We are delighted to announce that Prostate Cancer and Prostatic Diseases has achieved an Impact Factor of 6.9.
This milestone reflects the outstanding contributions of our authors, reviewers, editors, and readers.
#impact #prostate #clarivate #urosome

Patient satisfaction does not show whether information needed for shared decision-making was delivered. NLP analysis of consultation transcripts could quantify communication quality—but tools must support, not replace, clinical judgment.

🔗[doi.org/10.1038/s41391… ]

Itraconazole targets pathways linked to resistance in prostate cancer, but clinical activity in mCRPC remains modest. Biomarker-selected combinations and pharmacologic optimization are needed before repurposing can move into practice.

🔗[doi.org/10.1038/s41391… ] #mCRPC

In 968 patients with biochemical recurrence, cancer-specific mortality did not differ between Black and White men after prostatectomy or radiotherapy. Findings point toward modifiable access barriers—not biology—as drivers of disparities.

🔗[doi.org/10.1038/s41391…]

More options do not automatically mean better LUTS/BPO care. Effective counseling should combine clinical factors, patient values, surgical expertise and local resources to support the right treatment for each patient.
🔗[doi.org/10.1038/s41391…] #LUTS #BPH #SharedDecisionMaking

Single-port transvesical simple prostatectomy remained feasible across prostates >80 mL, including >160 mL. Volume increased operative time and blood loss but was not independently associated with complications. Further validation is needed.

🔗[doi.org/10.1038/s41391… ] #BPH

As MRI entered routine diagnostics in the Netherlands, negative biopsies fell from 49% to 29%, Grade Group ≥2 detection rose from 30% to 53%, and biopsy–prostatectomy concordance improved.

🔗[doi.org/10.1038/s41391… ] #ProstateCancer #MRI

Adding hormonal therapy to salvage radiotherapy after prostatectomy improved disease control in a meta-analysis of 4,536 patients—but not overall survival. Intensification should remain individualized.

🔗[doi.org/10.1038/s41391…] #ProstateCancer

In mHSPC, clinical fitness and selected genomic alterations helped distinguish extraordinary response from early resistance to ADT plus ARPI. Findings may inform—but not yet determine—treatment selection.

🔗[doi.org/10.1038/s41391…] #ProstateCancer

Not all inherited prostate cancer risk predicts lethal disease. In 14,644 men, pathogenic variants in selected DNA-repair genes and KLK3 I179T identified higher prostate cancer-specific mortality, including localized disease.
🔗[doi.org/10.1038/s41391…] #ProstateCancer

Could prostate fibrosis be an actionable driver of LUTS/BPH? This review maps the biological rationale, candidate antifibrotic therapies and future diagnostics. Translation will require patient selection and clinical validation.

🔗[doi.org/10.1038/s41391…]
#BPH #LUTS

At 24 months, the tissue-preserving Zenflow Spring System delivered sustained improvements in symptoms, quality of life and urinary flow in 72 men with BPH. Promising pilot evidence now requires comparative confirmation.

🔗[doi.org/10.1038/s41391…] #BPH #LUTS

Focal therapy seeks a balance between cancer control and quality of life, but enthusiasm must not outrun evidence. Careful patient selection, rigorous follow-up and robust long-term comparative data remain essential.

🔗[doi.org/10.1038/s41391…] #ProstateCancer #FocalTherapy

Cribriform pattern and intraductal carcinoma predicted biochemical recurrence after radical prostatectomy (adjusted HR 2.59) in this meta-analysis. Standardized reporting may strengthen postoperative risk stratification.

🔗[doi.org/10.1038/s41391…] #ProstateCancer #Pathology

Biochemical recurrence after radical prostatectomy raises 3 practical questions: when PSMA-PET adds value, how far salvage radiotherapy should extend and who benefits from ADT. Early treatment and individualized risk remain central.

🔗[doi.org/10.1038/s41391…] #ProstateCancer

Single-cell RNA sequencing is redefining prostate epithelial identity. Newly recognized states across normal, castrated and inflamed tissue reveal remarkable plasticity—and may reshape our understanding of regeneration and carcinogenesis.
🔗[doi.org/10.1038/s41391…]

PROTEUS moves radical prostatectomy into a multimodal era: perioperative apalutamide plus ADT reduced the risk of metastasis or death by 20%. The next challenge is selecting who truly needs intensification.

🔗[doi.org/10.1038/s41391…] #ProstateCancer

In post-hoc analyses of two abiraterone trials, concomitant ACE inhibitor/ARB use was associated with longer rPFS, overall survival and prostate cancer-specific survival. Hypothesis-generating evidence—not a basis for treatment selection.

🔗[doi.org/10.1038/s41391… ]

💊 In patients receiving abiraterone, concomitant ACEI/ARB use was associated with longer progression-free, overall, and prostate cancer–specific survival. Further prospective validation is needed. 📈

🔗 [rdcu.be/fwUCX]

🤖 Single-port transvesical prostatectomy was feasible even for very large prostates: larger glands increased operative time and blood loss, but not complications or functional outcomes.

🔗[rdcu.be/fwUup]

🔍 What predicts lasting success after prostatic urethral lift for BPH? In a pooled analysis of 331 men, more implants and higher implant density reduced 1-year retreatment risk, while lower baseline IPSS predicted better durability at 5 years. 📈

🔗 [rdcu.be/fwUqK]